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on therapy used more health care resources and were more costly during the
12-month observation period.
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OBJECTIVES: Proton pump inhibitors (PPIs) are the treatment of choice for gastro-
esophageal reflux disease (GERD), yet many patients experience persistent symp-
toms. To date, the burden of illness (BoI) among partial responders to PPI treatment
is not well understood. METHODS: REMAIN-France was a multicentre, 12-month
prospective study of adults with GERD who were newly identified as partial re-
sponders to optimised PPI treatment. BoI was evaluated at baseline, 3, 6, 9 and 12
months via patient-completed questionnaires, including the Reflux Symptom
Questionnaire with 7-day recall (RESQ-7). Medical evaluations were completed at
baseline, 6 and 12 months. Healthcare consumption was evaluated in terms of
visits to a primary care physician (PCP) and gastroenterologist, number of endos-
copies and days on prescribed GERD medication. All analyses were descriptive.
RESULTS: A total of 262 patients were enrolled (mean age, 54y; 40.5% men), the
majority of whom (n226, 86%) completed the 12-month study. Using the RESQ-7
questionnaire, 32% of patients reported severe symptoms and 48% reported daily
symptoms at baseline despite PPI treatment. Whilst continuing to receive pre-
scribed GERD medication (most commonly daily PPIs), symptoms remained bur-
densome at 6 and 12 months and indicated a positive relationship with impaired
quality of life (SF-36, EQ-5D) and decreased work productivity (WPAI-GERD). Be-
tween baseline and 6 months, the mean number of visits to a PCP and gastroen-
terologist among all patients was 1.9 and 0.5, respectively. For 7-12 months’ follow
up the corresponding figures were 1.8 and 0.4, respectively. A total of 12 patients
(4.6%) underwent endoscopy in the first 6 months of follow-up; thereafter, 10 pa-
tients (3.9%) underwent endoscopy between 7 and 12 months. CONCLUSIONS: In
French patients with GERD who have persistent symptoms despite PPI therapy, the
symptom burden is substantial and a positive relationship with impaired quality of
life and decreased work productivity is indicated. Supported by AstraZeneca R&D,
Mölndal, Sweden.
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OBJECTIVES: Flu-like symptoms (pyrexia, chills, myalgia and arthralgia) are expe-
rienced by 30%-50% of chronic hepatitis C (CHC) patients undergoing combination
interferon and ribavirin (RBV) treatment and are often cited as reasons for discon-
tinuation. To track these symptoms, the Hepatitis Physical Symptom Severity Di-
ary (HPSS-D), was developed.METHODS: Four items from the HPSS-D comprise the
Flu-Like Symptom Index (Index): fever, chills, muscle aches/pain, and joint pain.
Response options ranged from 0 (no symptoms) to 10 (worst symptom/problem)
over the past 24 hours. The diary was completed for 7 consecutive days at baseline
and weeks 4, 8 and 12. Data from two Phase 2b studies of treatment-naïve patients
comparing pegIFNalpha2a/RBV (peg-alfa) to peg-INF Lambda/RBV (peg-lambda)
and peg-alfa to peg-alfa and direct acting antiviral were combined. Measurement
properties were assessed. Mean and change scores and proportions of patients
reporting flu-like symptoms were calculated. RESULTS: Measurement properties
of the Index were supported with test-retest ICC value of 0.85, Cronbach’s alpha
range: 0.73-0.81, low to moderate construct validity [range: 0.23-0.63], and demon-
strated known groups validity (based on physician-reported flu symptoms). Re-
sponsiveness coefficients suggested a small to medium effect (SES0.40;
SRM0.39). MIDs were 2.5-3.0 points. Mean Index scores at week 12 for the peg-alfa
group (N36) increased from baseline by 2.39  4.95 versus 0.83  5.05 for peg-
lambda patients (N26). The percentage reporting any flu-like symptoms was sig-
nificantly higher for peg-alfa (75%) versus peg-lambda patients (27%) at week 12,
(p0.001), despite similar baseline rates. Fewer peg-lambda versus peg-alfa pa-
tients (50% versus 82%) experienced clinically significant worsening of flu-like
symptoms. CONCLUSIONS: PRO measures are important parameters to gauge pa-
tients’ experience with treatment, providing systematic assessment of treatment
benefit and side effects. This new Flu-Like Symptom Index from the HPSS-D dem-
onstrated adequate measurement properties and detected lower intensity and fre-
quency of flu-like symptoms for peg-lambda versus peg-alfa patients.
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OBJECTIVES: To develop and validate a clinically useful instrument for assessing
the impact of gastrointestinal symptoms (GI) on the health-related quality of life
(HRQoL) of solid organ transplant (SOT) patients (kidney, liver, heart or lung).
METHODS: Two phases: the Mypaciente-1 study was an epidemiological, cross-
sectional, multicentre study in which the SIGIT-QoL® questionnaire (17 items) was
developed and its reliability, feasibility and validity (content and construct) were
proven. At second, an observational, prospective, multicentre study, the Mypaci-
ente-2, was implemented to assess the test-retest reliability and the sensitivity to
change of the SIGIT-QoL®. SOT patients aged18, who had received the graft 3-24
months before and suffering from GI, were evaluate at baseline, 1-2 weeks and 3
months after baseline. Data recorded: age, sex, SOT type, acute allograft rejection
(AAR), GI etiology, Clinical and Patient global Impression scale (CGI-SI&GI and PGI-
SI&GI) and the SIGIT-QoL® (range: 0-maximum impact to 68-minimum disrup-
tion). Intraclass correlation (ICC), differences between baseline and last visit (Wil-
coxon test), effect size (Cohen’s d), the minimal important difference –MID- (using
CGI & PGI as anchors in General Linear Models) and the cut-off score (ROC analysis)
were calculated. RESULTS: In the Mypaciente-2 study 277 SOT patients (61.4%
males) were included. Mean age (SD) was 52.69(11.65) years, time since transplan-
tation was 12.31(6.74) months and 22.4% suffered AAR. At baseline, SIGIT-QoL®
scores: 51.21(11.25) showed an impact on patients’ HRQoL that diminished 3
months later: 57.40(8.38;p0.001). SIGIT-QoL® test-retest reliability was adequate
(ICC0.740-0.895). A high-moderate effect size (d-0.590) was found. Moreover,
MID of 4.2 points in total scores were found (F4,22316.917,p0.001 and
F4,22425.138,p0.001). Finally, a cut-off point (55.00 points) was estimated
(AUC0.846,p0.001; sensitivity0.793; specificity0.713; negative likelihood ra-
tio0.290; positive likelihood ratio2.762). CONCLUSIONS: The SIGIT-QoL® is a
feasible (average completion time lower than 6.5 minutes), reliable and valid in-
strument for assessing the impact of GI symptoms on SOT patients.
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OBJECTIVES: Hepatitis C virus (HCV) infection is associated with fatigue, anxiety,
and depression. Little is known, however, about the effect of sleep disturbances on
health-related quality of life (HRQoL), and what factors are associated with such
disturbances. METHODS: This study is based on data from the EU National Health
and Wellness Survey (N57,805), a cross-sectional database representative of the
adult EU population. Patients who reported being diagnosed with HCV by a physi-
cian and provided household income and body weight information were included
for analysis (N301). Patients who reported experiencing insomnia or sleep diffi-
culty symptoms in the past year (n135) were compared with patients who did not
experience such symptoms (n166). Sleep group membership was predicted with
a logistic regression model, while mental and physical HRQoL (SF-12) were pre-
dicted with multiple regression models. Covariates included age, gender, marital
status, education, income, employment, BMI, exercise and smoking habits, alcohol
use, and physician diagnosed HIV/AIDS, hepatitis B, anxiety disorder, and
depression. RESULTS: HCV patients with sleep disturbances were significantly
younger (48.8 vs. 51.7) and more likely to be diagnosed with HIV/AIDS (8.1% vs.
2.4%), an anxiety disorder (56.3% vs. 22.9%), and depression (48.9% vs. 10.8%)
(ps0.05) than patients with no sleep disturbances. After controlling for potential
confounders, anxiety disorder (OR2.2) and depression (OR5.1) were the only
significant predictors of sleep disturbances (ps0.05). SF-12 mental HRQoL scores
were significantly associated with age (b0.2), anxiety disorder (b -5.7), depres-
sion (b -5.9), and sleep disturbances (b -5.1, ps0.05). SF-12 physical HRQoL
scores, however, were not associated with sleep disturbance. CONCLUSIONS: De-
spite the strong association of anxiety disorder and depression with sleep distur-
bances among HCV-infected individuals, sleep disturbances had an independent
and significant effect on mental HRQoL in this population. The results suggest
effective treatment of disturbed sleep may improve the quality of life of HCV pa-
tients.
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OBJECTIVES: Active ulcerative colitis (UC) negatively impacts patients’ health-re-
lated quality of life (HRQoL); thus a fundamental goal of treatment is to achieve and
maintain disease remission. The current analysis examines how long-term main-
tenance treatment with a multi-matrix (MMX) oral formulation of mesalamine
impacted disease-specific HRQoL in patients with quiescent UC. METHODS: This
analysis examined the 12-month maintenance phase of a two-phase, multicenter,
open-label study, during which patients with quiescent UC at baseline received
MMX mesalamine 2.4 g/day QD. Disease-specific HRQoL was measured at baseline,
six-month, and twelve-month (endpoint) visits using the Shortened Inflammatory
Bowel Disease Questionnaire (SIBDQ), which measures 4 domains: bowel symp-
toms, systemic symptoms, emotional function and social function. Changes in
SIBDQ domains and total score over time were assessed using repeated-measures
analysis of variance. Correspondence between disease-specific HRQoL and disease
activity was assessed using analysis of covariance to compare SIBDQ scores at
month 12 between clinically recurrent and non-recurrent patients while control-
ling for age, gender, and BMI. RESULTS: Data were collected from 203, 144, and 157
patients at baseline, 6-month, and 12-month/early withdrawal visits, respectively.
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For the overall patient sample, no statistically significant changes across visits was
observed for any SIBDQ domain or total score (all P0.05); mean change from
baseline to endpoint did not exceed 3% for any SIBDQ score. At endpoint, patients
exhibiting recurrent UC (n29) scored significantly lower than non-recurrent pa-
tients (n117) on bowel symptoms, emotional function, and social function do-
mains and total score (P0.001 for all differences). CONCLUSIONS: Patients with
quiescent UC receiving daily treatment with MMX mesalamine (2.4 g/day) exhib-
ited high stability, and thus strong maintenance, in disease-specific HRQoL over
the course of one year. The majority of patients remained in clinical remission
following one year of this treatment regimen. Patients with clinically recurrent UC
showed significantly worse HRQoL outcomes than non-recurrent patients.
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OBJECTIVES: Chronic liver disease is responsible for approximately 40,000 deaths
annually, which corresponds to about 2% of all deaths worldwide. This study aimed
to specify and understand the characteristics of patients with LC service followed
in the Gastroenterology at CHCB as well as assess the severity of LC using the scale
of Child-Pugh-Turcotte and the Health Related Quality Of Life. METHODS: This is a
retrospective, observational and cross for the evaluation of QdVS a group of pa-
tients diagnosed with LC in CHCB. Direct interviews were carried out using ques-
tionnaires to a sample of 42 patients with clinical and imaging during the months
of January and April 2011. Besides the descriptive analysis we tried to establish
some correlations between the variables studied, considered statistically signifi-
cant when p value is 0.05. RESULTS: The mean age of study participants was 62
years, and approximately 31% of patients were between 66 and 75 years. The males
and ethylic etiology of cirrhosis accounted for a proportion of over 90% of all pa-
tients. The average score obtained after applying the SF-36 was around 49%. After
the calculation made to stratify the severity of the disease across the range of CPT,
69% of patients were in class A, class B 21% and 10% to class C. CONCLUSIONS: The
LC mainly affects males, and regular alcohol consumption the predominant etiol-
ogy. Regarding the scale of CPT, the results indicate a good survival. We conclude
that the QdVS is clearly affected in CLD associated with LC, particularly in terms of
physical pain, physical performance and vitality. This study is consistent with
national data, where the Liver Cirrhosis is a public health problem, for which mea-
sures must be taken concerning the excessive consumption of alcoholic beverages.
PGI30
COMPARISON OF HEALTH RELATED QUALITY OF LIFE BETWEEN HEPATITIS,
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OBJECTIVES: As a result of successful treatments for chronic hepatic diseases
(CHDs), patients generally live longer but often with a compromised wellbeing. We
assessed Health-Related Quality-of-Life (HRQoL) of CHDs adult patients.
METHODS: A naturalistic multicentre Cost-of-Illness study was conducted. Adult
patients (age18 years) diagnosed with CHDs, consequently accessing at gastro-
enterology unit of 2 hospitals, were enrolled. Direct, indirect and intangible costs
were estimated from the societal perspective. The patients were sub-grouped ac-
cording to their main condition at the enrollment: hepatitis B and/or C, cirrhosis,
liver transplantation, hepatic carcinoma. HRQoL was assessed with the EQ-5D 3L
and 5L versions (the psychometric properties of the 5L new version was previously
discussed: podium by Scalone et al, 13th ISPOR Congress 2011, Prague). The follow-
ing results pertain the EQ-5D-5L results.RESULTS:We enrolled 1,088 valid patients,
62% male, aged 19-90 (median60) years. Patients with hepatitis were 60.4%, 20.2%
had cirrhosis, 11.9% had liver transplantation, 7.5% hepatic carcinoma. Among all
the patients, the meanSD VAS was 69.120.8. Mobility was an extreme/severe
problem for 3.3% and a moderate/slight problem for 22.6% of the patients. Self-care
was an extreme/severe problem for 1.2% and a moderate/slight problem for 11.5%
of the patients. Usual activities was an extreme/severe problem for 4.0% and a
moderate/slight problem for 25.5% of the patients. Pain/discomfort was extreme/
severe for 3.2% and a moderate/slight problem for 36.1% of the patients. Anxiety/
Depression was extreme/severe for 4.5% and a moderate/slight for 43.5% of the
patients. Patients with cirrhosis reported the worst levels of HRQoL, those with
carcinoma had a worse HRQoL than patients with transplantation, those with hep-
atitis reported better levels of HRQoL.CONCLUSIONS:Our study shows how HRQoL
is negatively related with the severity and chronicity of CHDs. Health technology
aimed to improve wellbeing in patients with disabling long term hepatic disease is
required.
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OBJECTIVES:Ulcerative colitis (UC) impairs patients’ productivity in the workplace.
While studies have shown increased productivity in patients with active UC fol-
lowing treatment with a multi-matrix (MMX) oral formulation of mesalamine, the
current analysis is the first to examine maintenance of work-related outcomes
(WRO) in patients with quiescent UC who received one year of MMX mesalamine
treatment. METHODS: Data were from a multicenter, open-label study of patients
with quiescent UC who received MMX mesalamine 2.4 g/day QD for twelve months.
The Work Productivity and Activity Impairment Questionnaire: Specific Health
Problem (WPAI:SHP), administered at baseline, six-month, and twelve-month vis-
its, measured the impact of a patient’s UC on 4 domains: absenteeism, presentee-
ism, overall productivity, and impairment in non-work activities. Repeated-mea-
sures analysis of variance assessed change in scores across visits. Analysis of
covariance assessed the association between WRO and disease activity (covariates:
age, gender, and BMI) by comparing WPAI:SHP scores between patients with clin-
ically recurrent and non-recurrent UC at 12 months. RESULTS: WPAI:SHP scores
were collected from 198 patients at baseline, 142 patients at six months, and 154
patients at 12 months/early withdrawal (endpoint). Stability of WRO across 12
months for the overall sample was evidenced by baseline-endpoint changes in
mean scores of 2% for each WPAI:SHP scale, with no statistically significant dif-
ferences across visits (all P0.05). Patients with clinically recurrent UC at month 12
(n29) scored significantly worse than non-recurrent UC patients (n113) on pre-
senteeism, overall productivity, and activity impairment, P0.05 for differences.
CONCLUSIONS: Patients with quiescent UC who received MMX mesalamine 2.4
g/day QD showed stable WRO over the course of one year. Findings indicate that
long-term MMX mesalamine treatment was associated with maintenance of WRO
for patients with quiescent disease. This treatment regimen maintained clinical
remission for the majority of patients, with recurrent patients showing worse WRO
than non-recurrent patients.
Gastrointestinal Disorders – Health Care Use & Policy Studies
PGI32
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OBJECTIVES: Regardless of the wide variation in estimated incidence rates for
post-operative ileus (POI), it is widely understood that gastrointestinal complica-
tions represent the most common post-operative morbidity type. In addition to the
patient burden, the extension of hospital stay caused by POI (estimated to be be-
tween 3.2 and 8 days) can have an enormous economic impact, making this an
important area of research. The objective of this literature review was to explore
the various interventions investigated for the acceleration of gastrointestinal re-
covery after surgery and reduction of POI. METHODS: Comprehensive literature
searches across online databases and horizon scanning were used to identify rel-
evant literature. Literature was gathered on any intervention that had been as-
sessed in a randomised clinical trial for the treatment of POI following abdominal
surgery.RESULTS:Over 600 studies were identified as potentially relevant. Approx-
imately one quarter of these assessed the broad spectrum of prokinetic pharma-
cological agents for the treatment of POI, as well as antiemetics, antibiotics and
anaesthetics. In particular, research into new ghrelin agonists is underway. Next to
this, the unfavourable effects of opioid analgesics on GI recovery were studied in
numerous trials. Non-pharmacological methods to enhance recovery after surgery
such as gum chewing, acupuncture and early feeding have also been investigated
with mixed success. Many of the trials identified were dated, illustrating how long
POI has remained an unresolved issue for clinicians and patients. CONCLUSIONS:
Many different types of treatment, with varying mechanisms of action, have been
clinically studied for the prevention or treatment of POI over the past 40 years.
However, there is still no standard management paradigm to accelerate post-op-
erative bowel recovery. The absence of an effective pharmacological agent licensed
for this indication in Europe and significant variance in practice suggest an unmet
clinical need, which should shape future research in this area.
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PREDICTORS OF DIRECT MEDICAL COSTS OF CROHN’S DISEASE AND
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OBJECTIVES: Cost predictions are useful to identify patients with special needs
early. Crohn’s disease (CD) and ulcerative colitis (UC) are complex conditions which
are classified as Inflammatory Bowel Diseases (IBD). Disease onset in early adult-
hood leads to a long period of healthcare utilisation. The goal of this study was to
determine the effect of disease activity and disease history on overall medical costs
and to determine whether additional factors predict costs for CD and UC.
METHODS: Medical history, demographic information and healthcare use (4
weeks) were reported by German IBD-Association members. Healthcare costs were
calculated using national sources. Disease activity was determined using a German
IBD Index. Patients classified their disease history as constantly-active, intermit-
tently-active or in remission. Other factors evaluated were education, marital sta-
tus, health insurance, an IBD-related operation (at least 3 months ago), smoking
status and employment status. Missing values for determinants were imputed
using the Markov-chain-Monte-Carlo method. Cost determinants were analysed
using a gamma regression model, adjusting for age, sex, disease duration and for
previous colectomy in UC patients. Costs of CD and UC were analysed separately.
RESULTS: The 4-week mean direct medical costs were 424.44€ for CD (n241) and
365.79€ for UC (n238). Mean disease activity (CD: 3.3 UC: 3.2) was similar between
the groups and 46% of both CD and UC subjects reported disease history as in
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